Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
A Study to Assess Etoricoxib Versus Diclofenac in Chinese Patients With Osteoarthritis of the Knee or Hip (0663-080)(COMPLETED)
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 160
- Registration Number
- NCT00140972
A Study to Assess the Effect of Montelukast Sodium With Concomitant Administration of Inhaled Budesonide in Asthmatic Patients (0476-075)
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 546
- Registration Number
- NCT00140946
A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-08-22
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 450
- Registration Number
- NCT00132717
Effects of Ezetimibe With Simvastatin in the Therapy of Adolescents With HeFH (Study P02579)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-08-11
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 248
- Registration Number
- NCT00129402
An Approved Drug to Study a New Indication for Allergic Rhinitis (0476-327)
- First Posted Date
- 2005-08-08
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1375
- Registration Number
- NCT00127647
Two Investigational Drugs in the Prevention of Airway Constriction Brought on by Exercise in Participants With Asthma (0476-911)
- First Posted Date
- 2005-08-05
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 154
- Registration Number
- NCT00127166
A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia (0906-140)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-08-05
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 600
- Registration Number
- NCT00127179
A Study of an Intravenous Drug in Pediatric Patients With Acute Asthma (0476-301)
- First Posted Date
- 2005-07-06
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 276
- Registration Number
- NCT00117338
Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-072)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-05-25
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 393
- Registration Number
- NCT00111722
Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-071)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-05-25
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 393
- Registration Number
- NCT00111709
© Copyright 2024. All Rights Reserved by MedPath